期刊
ENDOCRINE-RELATED CANCER
卷 22, 期 5, 页码 R279-R300出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-15-0355
关键词
antiestrogen; aromatase inhibitor; breast cancer; endocrine-resistance; estrogen receptor; miRNA; tamoxifen
资金
- National Institutes of Health [R01 CA138410]
- University of Louisville School of Medicine
Therapies targeting estrogen receptor alpha (ER alpha), including selective ER modulators such as tamoxifen, selective ER downregulators such as fulvestrant (ICI 182 780), and aromatase inhibitors such as letrozole, are successfully used in treating breast cancer patients whose initial tumor expresses ER alpha. Unfortunately, the effectiveness of endocrine therapies is limited by acquired resistance. The role of microRNAs (miRNAs) in the progression of endocrine-resistant breast cancer is of keen interest in developing biomarkers and therapies to counter metastatic disease. This review focuses on miRNAs implicated as disruptors of antiestrogen therapies, their bona fide gene targets and associated pathways promoting endocrine resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据